New initiative aims to transform how Alzheimer’s disease is diagnosed, treated across healthcare settings

3 minutes, 30 seconds Read



Members of the AD-RIDDLE consortium announced today that they will launch a new initiative aimed at bridging the gap between Alzheimer’s research, implementation science and precision medicine. The AD-RIDDLE program provides a suite of validated solutions for the timely detection and diagnosis of Alzheimer’s disease and dementia by enabling healthcare professionals to match the right intervention with the right intervention at the right time, enabling people to better understand what they can do to reduce risk. will do Prevent cognitive decline.

Alzheimer’s disease represents a major public health challenge. In Europe alone, approximately 7 million people are living with Alzheimer’s disease, a number that is expected to double by 2050. There is a critical need for effective preventive, diagnostic and therapeutic solutions, implemented at scale and for increased involvement of individuals and caregivers, including disease prevention, management and care. The advent of disease-modifying therapies will lead more people to diagnosis and treatment. Although this primarily represents an increasing cost to the health system and society, it also presents great potential for prevention, opportunities for more timely diagnosis and personalized treatment options, and overall health-economic benefits in the long term.

With new research on the efficacy of multi-domain lifestyle interventions and the promise of disease-modifying therapeutics, there is renewed hope for patients, caregivers, and health care providers and a window of opportunity for substantial progress. AD-RIDDLE represents the greatest opportunity yet for cross-sector advances in Alzheimer’s research and care.”


Mia Kivipelto, Professor, Research Director and Senior Geriatrician at Karolinska Institute and Karolinska University Hospital and Principal Investigator (PI) for the AD-RIDDLE project

Thanks to funding from the Innovative Health Initiative (IHI) and UK Research and Innovation (UKRI), the AD-RIDDLE consortium will embark on a five-year effort to transform how Alzheimer’s disease (AD) is detected, diagnosed and treated across healthcare settings. . . The consortium brings together academic and industry partners, healthcare providers, regulatory agencies and patient organizations, bringing together a mix of world-class research, clinical practice, diagnostics, advanced analytics and data platform capabilities in the project. AD-RIDDLE builds on existing technologies, biomarkers, tools and interventions developed by consortium partners through a number of previous EU-funded initiatives, including studies building on Professor Kivipelto’s ground-breaking finger research.

AD-RIDDLE aims to unlock expertise in AD diagnosis and treatment, removing barriers to entry that have traditionally slowed patient access to healthcare providers and precision medicine. The project will develop a modular toolbox platform designed to provide support at all stages of the clinical pathway, including:

  • A digital community engagement portal with self-directed assessment tools for older adults, timely referral pathways to health care providers, and useful and actionable resources.
  • An array of screening tools for increased accuracy in risk identification and early diagnosis, including digital cognitive assessment and blood-based biomarkers.
  • A decision support toolkit for healthcare providers, powered by validated algorithms for differential diagnosis, prevention and care.
  • Personalized patient therapy that can be physician-assisted or self-directed, including lifestyle interventions and pharmacological treatments, matches patients with the right intervention at the right time.

The AD-RIDDLE platform will allow for flexible adaptation and application in a variety of settings, from memory clinics to primary care and beyond the healthcare system to larger populations. A real-world pilot study will be conducted in these settings across six European countries and will provide comprehensive evidence to support the implementation of diagnostic tools, treatments and lifestyle interventions. Study data will be hosted in a GDPR-compliant manner on the European Platform for Neurodegenerative Diseases (EPND), an IMI2-funded initiative that will make datasets available for additional research and discovery aimed at facilitating new discoveries in neurodegenerative diseases. Research.

“AD-RIDDLE will rapidly advance the “last mile” of innovation, bridging Alzheimer’s care pathways from research to the real-world setting in an efficient and effective manner based on high-quality data. Niranjan Bose, Managing Director, Health & Life Sciences, Gates Ventures and co-led the project. “AD-RIDDLE will generate real-world evidence for clinical implementation of precision diagnostics, interventions and therapies, and drive new research on Alzheimer’s disease by making datasets available through EPND.”

With the broad participation of patients and clinical experts across a diverse mix of healthcare settings in the EU, AD-RIDDLE will empower patients with effective guidelines to address their cognitive health and advance Alzheimer’s research.



Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *